Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
Status:
Recruiting
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
The objective of the proposed work is to determine whether administration for 12 months of
romosozumab followed by 12 months of denosumab will maintain bone mass at the knee in
subjects with subacute SCI compared to 24 months of denosumab administration alone.